ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 886

Mesenchymal Stem Cell Senescence Alleviates Their Chondrogenic and Seno-Suppressive Properties, Contributing to Osteoarthritis Development

Olivier Malaise1, Yassin Tachikart 2, Michael Constantinides 2, Marcus Mumme 3, Daniele Noel 2, Jing Wang 4, Christian Jorgensen 2 and Jean-Marc brondello 2, 1GIGA Research, CHU and University of Liège, Liège, Belgium, 2IRMB, INSERM U1183, University of Montpellier, Montpellier, France, 3University Hospital of Basel, Basel, Switzerland, 4INM, INSERM U1050, University of Montpellier, Montpeller, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: mesenchymal stem cells and Senescent Cells, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S105: Osteoarthritis & Joint Biology – Basic Science (886–891)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Tissue accumulation of p16INK4A-positive senescent cells is associated with age-related disorders such as osteoarthritis (OA). These senescent cells induce a tissue loss of function through a particular secretory phenotype called SASP (senescence-associated secretory phenotype). Links between OA onset and cellular senescence remain poorly detailed. We wanted to determine the presence of articular senescent cells in in vivo OA mouse models and study the involvement of mesenchymal stem cells (MSC) senescence in OA pathogenesis.

Methods: Wild-type mice C57BL/6, SAMP8/R1 (senescence accelerated mouse-prone and resistant), transgenic p16INK4A +/Lucand p16INK4ALuc/Lucwere used. Experimental OA was induced by intraarticular injections of collagenase (CIOA).

Results: (1) CIOA was induced in senescence-driven luciferase transgenic mice. Under CCD camera, a peak in luminescence was detected revealing the presence of senescent cells in the joint. Remarkably, articular senescence also contributes to OA: mice deficient in p16INK4a, a main senescence-driving known cell cycle inhibitor, were partially protected against CIOA. These results were confirmed in C57Bl/6 mice after CIOA by showing an increase in gene expression for senescence in the synovial tissue.
(2) MSCs found in synovial, cartilage, fat pad and bone marrow participate in joint homeostasis. Because MSC are at the root of OA development, we hypothesize that cellular senescence onset in these progenitors would be a possible etiological factor for OA. We stablished an in vitro p16INK4A-induced senescence model on human MSC: their intrinsic properties (self-renewing and chondrogenesis) are altered when senescent. In co-culture conditions with chondrocytes from OA patients, senescent MSC lost their extrinsic chondroprotective properties.
(3) To in vivo challenge these findings, we rely on the mouse model of accelerated senescence SAMP8, which develop spontaneous OA at the age of 6 months with cartilage degradation, synovial hypertrophy, osteophytosis and subchondral bone remodelingassociated to meniscal calcification (micro-tomography). Isolated MSC from these mice express senescence (p16INK4a, p21waf1, MMP13, TGF-β1). Intra-articular injection of these isolated SAMP8-derived MSC compared to SAMR1-derived control MSC, in young wid-type C57Bl/6 mice, was suffisant by its own, to induce significant articular cartilage degradation (OA score of 12.2 ± 1.5 vs 6.1 ± 3.5 for SAMP8 and SAMR1 MSC respectively. p < 0.05).

Conclusion: p16INK4A-induced cellular senescence in MSC played a causative role in cartilage loss of function and OA pathogeny. In vitro, senescent MSC show altered intrinsic and extrinsic supportive tissue functions.In vivo, intra-articular injection of senescent MSC induced cartilage degradation. Specific targeting of such deleterious senescent cells could be an innovating and promising treatment in OA.


Disclosure: O. Malaise, None; Y. Tachikart, None; M. Constantinides, None; M. Mumme, None; D. Noel, None; J. Wang, None; C. Jorgensen, None; J. brondello, None.

To cite this abstract in AMA style:

Malaise O, Tachikart Y, Constantinides M, Mumme M, Noel D, Wang J, Jorgensen C, brondello J. Mesenchymal Stem Cell Senescence Alleviates Their Chondrogenic and Seno-Suppressive Properties, Contributing to Osteoarthritis Development [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/mesenchymal-stem-cell-senescence-alleviates-their-chondrogenic-and-seno-suppressive-properties-contributing-to-osteoarthritis-development/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mesenchymal-stem-cell-senescence-alleviates-their-chondrogenic-and-seno-suppressive-properties-contributing-to-osteoarthritis-development/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology